

The following is a representative list of topics that our transactional and regulatory healthcare and life sciences partners can discuss during the JPM25 week. We invite you to select the topics that are of key interest to your company. Additionally, please let us know if there are other issues that are top of mind but not listed here. We will customize your Client Conference agenda to suit your company's interests.



Transactions

- Healthcare & Life Sciences transactions market update - Recent trends and impact on deal structuring
- Overview of funding opportunities for Biotechs
- The ins and outs of carve-outs and spin-offs
- Post-acquisition integration and corporate restructuring
- Minority investments – Structuring approaches and working with minority investors
- Licensing & Collaborations – Major differences between M&A and licensing deals in the life sciences space; structuring approaches (LLC/ shareholder agreement / IP / co-development and co-commercialization)
- M&A and Compliance - Exploring the latest enforcement posture from the sanctions and ABAC regulators on liabilities for violations that come up in the acquisition / post-acquisition context
- Tech acquisitions for “non-tech” companies
- Modeling the impact of the Pillar 2 - Global Minimum Tax on M&A
- Geopolitical trends and impact on dealmaking
- Sustainable finance
- ESG risks / considerations for targets



Antitrust and Competition

- Tightening regulatory scrutiny of deals - Global antitrust and competition trends including foreign investment and merger control scrutiny
- Enforcement trends in the Healthcare & Life Sciences Industry



Investigations

- Global compliance and investigations trends
- Enforcement agencies' focus and strategies
- Managing reputational risk and market integrity



Regulatory

- Overview of the current regulatory landscape – impact on deal making, challenges and opportunities for life sciences businesses
 - Jurisdictional nuances: North America, Europe, Asia Pacific and Latin America
- Overview of new and upcoming legislation in the EU and the US impacting healthcare and life sciences companies (eg. EU HTA, EU Pharma Package, SoHO Regulation, EU Health Data space, US Inflation Reduction Act, US BioSecure Act...)
- An EU and Gulf perspective on the legal and policy landscape – implications and potential opportunities for life sciences businesses

[bakermckenzie.com](https://www.bakermckenzie.com)

© 2024 Baker & McKenzie LLP. All rights reserved. Baker & McKenzie International is a global law firm with member law firms around the world. In accordance with the common terminology used in professional service organizations, reference to a “partner” means a person who is a partner or equivalent in such a law firm. Similarly, reference to an “office” means an office of any such law firm. This may qualify as “Attorney Advertising” requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.